Your browser doesn't support javascript.
loading
US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer.
Shord, Stacy S; Zhu, Hao; Liu, Jiang; Rahman, Atiqur; Booth, Brian; Zineh, Issam.
Affiliation
  • Shord SS; Division of Cancer Pharmacology II (DCPII), Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
  • Zhu H; Division of Pharmacometrics (DPM), OCP, OTS, CDER, FDA, Silver Spring, Maryland, USA.
  • Liu J; Division of Pharmacometrics (DPM), OCP, OTS, CDER, FDA, Silver Spring, Maryland, USA.
  • Rahman A; Division of Cancer Pharmacology II (DCPII), Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
  • Booth B; Division of Cancer Pharmacology I (DCPI), OCP, OTS, CDER, FDA, Silver Spring, Maryland, USA.
  • Zineh I; OCP, OTS, CDER, FDA, Silver Spring, Maryland, USA.
CPT Pharmacometrics Syst Pharmacol ; 12(11): 1573-1576, 2023 Nov.
Article in En | MEDLINE | ID: mdl-37641498
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms Limits: Humans Country/Region as subject: America do norte Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms Limits: Humans Country/Region as subject: America do norte Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2023 Document type: Article